BidaskClub upgraded shares of XBiotech (NASDAQ:XBIT) from a buy rating to a strong-buy rating in a report published on Friday morning.
Separately, ValuEngine cut XBiotech from a buy rating to a hold rating in a report on Thursday, December 20th.
Shares of XBIT traded down $0.68 on Friday, reaching $10.94. The stock had a trading volume of 166,908 shares, compared to its average volume of 198,375. XBiotech has a twelve month low of $2.13 and a twelve month high of $11.74.
In related news, Director W Thorpe Mckenzie bought 24,838 shares of the stock in a transaction on Monday, December 24th. The shares were purchased at an average price of $5.88 per share, for a total transaction of $146,047.44. Following the acquisition, the director now owns 3,398,600 shares in the company, valued at $19,983,768. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Fondation Rennes bought 65,000 shares of the stock in a transaction on Wednesday, February 6th. The shares were bought at an average price of $9.19 per share, for a total transaction of $597,350.00. Following the acquisition, the insider now owns 3,590,182 shares in the company, valued at approximately $32,993,772.58. The disclosure for this purchase can be found here. In the last 90 days, insiders purchased 167,111 shares of company stock worth $1,342,333. Insiders own 37.00% of the company’s stock.
Large investors have recently made changes to their positions in the business. Virtu Financial LLC acquired a new stake in XBiotech during the 4th quarter valued at $80,000. Vanguard Group Inc grew its holdings in XBiotech by 5.5% during the 3rd quarter. Vanguard Group Inc now owns 834,523 shares of the biopharmaceutical company’s stock valued at $2,654,000 after buying an additional 43,648 shares during the last quarter. Finally, Vanguard Group Inc. grew its holdings in XBiotech by 5.5% during the 3rd quarter. Vanguard Group Inc. now owns 834,523 shares of the biopharmaceutical company’s stock valued at $2,654,000 after buying an additional 43,648 shares during the last quarter. Hedge funds and other institutional investors own 3.12% of the company’s stock.
XBiotech Inc, a pre-market biopharmaceutical company, engages in discovering and developing True Human monoclonal antibodies for treating various diseases. The company's lead product is Xilonix, which is also known as MABp1, a therapeutic antibody that neutralizes interleukin-1 alpha, which has completed Phase III clinical trial in Europe for the treatment of symptomatic and advanced colorectal cancer.
See Also: What is the Bid-Ask Spread?
Receive News & Ratings for XBiotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XBiotech and related companies with MarketBeat.com's FREE daily email newsletter.